Teladoc Inc (NYSE:TDOC) – Equities research analysts at Cantor Fitzgerald lowered their FY2017 earnings estimates for Teladoc in a research report issued to clients and investors on Wednesday. Cantor Fitzgerald analyst S. Halper now expects that the health services provider will earn ($1.83) per share for the year, down from their prior forecast of ($1.58). Cantor Fitzgerald has a “Hold” rating and a $31.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Teladoc’s FY2018 earnings at ($1.50) EPS.
TDOC has been the topic of a number of other reports. CIBC reissued an “outperform” rating and set a $45.00 price target (up from $40.00) on shares of Teladoc in a research report on Tuesday, November 21st. KeyCorp reissued a “buy” rating and set a $41.00 price target on shares of Teladoc in a research report on Wednesday, January 10th. Zacks Investment Research upgraded shares of Teladoc from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. ValuEngine upgraded shares of Teladoc from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Citigroup assumed coverage on shares of Teladoc in a report on Thursday, January 4th. They set a “buy” rating on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $39.31.
Teladoc (NYSE:TDOC) opened at $32.65 on Monday. The firm has a market cap of $1,980.00 and a price-to-earnings ratio of -22.52. Teladoc has a 52-week low of $15.65 and a 52-week high of $38.40. The company has a current ratio of 5.08, a quick ratio of 5.08 and a debt-to-equity ratio of 0.83.
Teladoc (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). The firm had revenue of $68.70 million for the quarter, compared to the consensus estimate of $67.53 million. Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The company’s revenue for the quarter was up 112.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.33) earnings per share.
In other Teladoc news, CEO Jason N. Gorevic sold 20,000 shares of Teladoc stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.10, for a total value of $642,000.00. Following the sale, the chief executive officer now directly owns 838,261 shares in the company, valued at approximately $26,908,178.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Mark Hirschhorn sold 30,000 shares of Teladoc stock in a transaction on Monday, December 4th. The shares were sold at an average price of $32.99, for a total transaction of $989,700.00. Following the completion of the sale, the chief financial officer now owns 5,203 shares in the company, valued at $171,646.97. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 150,000 shares of company stock worth $4,930,700. 4.47% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of the business. Raymond James Trust N.A. increased its stake in Teladoc by 36.2% in the 3rd quarter. Raymond James Trust N.A. now owns 9,943 shares of the health services provider’s stock valued at $330,000 after buying an additional 2,643 shares during the last quarter. American International Group Inc. increased its stake in Teladoc by 8.1% in the 3rd quarter. American International Group Inc. now owns 36,079 shares of the health services provider’s stock valued at $1,196,000 after buying an additional 2,697 shares during the last quarter. Swiss National Bank increased its stake in Teladoc by 4.8% in the 2nd quarter. Swiss National Bank now owns 59,500 shares of the health services provider’s stock valued at $2,065,000 after buying an additional 2,700 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Teladoc by 134.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after buying an additional 2,707 shares during the last quarter. Finally, Brown Advisory Inc. increased its stake in Teladoc by 38.3% in the 3rd quarter. Brown Advisory Inc. now owns 10,521 shares of the health services provider’s stock valued at $348,000 after buying an additional 2,915 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: “Cantor Fitzgerald Equities Analysts Reduce Earnings Estimates for Teladoc Inc (TDOC)” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/01/16/cantor-fitzgerald-equities-analysts-reduce-earnings-estimates-for-teladoc-inc-tdoc.html.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.